Release from quiescence of primitive human hematopoietic stem/progenitor cells by blocking their cell-surface TGF-β type II receptor in a short-term in vitro assay

Stem Cells

Volumn 18, Issue 2, 2000, Pages 102-111

  Fortunel, Nicolas ^a   Hatzfeld, Jacques ^a,c   Kisselev, Sergueï ^a   Monier, Marie Noëlle ^a   Ducos, Karin ^a   Cardoso, Angelo ^b   Batard, Pascal ^a   Hatzfeld, Antoinette ^a  

^a CNRS   (France)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UPR 1983   (France)

Author keywords

Hematopoiesis; HPP Q in vitro assay; Quiescence; Stem progenitor cell; TGF receptor

Indexed keywords

CD34 ANTIGEN; CD38 ANTIGEN; RECEPTOR ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2;

ARTICLE; CELL ACTIVATION; CELL PROLIFERATION; CELL SUBPOPULATION; CONTROLLED STUDY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; RECEPTOR BLOCKING; SIGNAL TRANSDUCTION;

EID: 0034070464     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1634/stemcells.18-2-102     Document Type: Article

References (68)

1. Becker AJ, McCulloch EA, Siminovitch L et al. The effect of differing demands for blood cell production on DNA synthesis by hematopoietic colony-forming cells of mice. Blood 1965;26:296-308.
2. Hodgson GS, Bradley TR. Properties of hematopoietic stem cells surviving 5-fluorouracil treatment: evidence for a pre-CFU-S cell? Nature 1979;281:381-382.
3. 0 periods and constant doubling rates of early pluripotent hemopoietic progenitors. J Cell Physiol 1983;117:308-318.
4. Berardi AC, Wang A, Levine JD et al. Functional isolation of human hematopoietic stem cells. Science 1995;267:104-108.
5. Ohta M, Greenberger JS, Anklesaria P et al. Two forms of transforming growth factor-β distinguished by multipotential haematopoietic progenitor cells. Nature 1987;329:539-541.
6. Keller JR, McNiece IK, Sill KT et al. Transforming growth factor β directly regulates primitive murine hematopoietic cell proliferation. Blood 1990;75:596-602.
7. Ploemacher RE, Van Soest PL, Boudewijn A. Autocrine transforming growth factor β1 blocks colony formation and progenitor cell generation by hemopoietic stem cells stimulated with steel factor. STEM CELLS 1993;11:336-347.
8. Jacobsen SEW, Veiby OP, Myklebust J et al. Ability of flt3 ligand to stimulate the in vitro growth of primitive murine hematopoietic progenitors is potently and directly inhibited by transforming growth factor-β and tumor necrosis factor-α. Blood 1996;87:5016-5026.
9. Ohishi K, Katayama N, Itoh R et al. Accelerated cell-cycling of hematopoietic progenitors by the flt3 ligand that is modulated by transforming growth factor-β. Blood 1996;87:1718-1727.
10. Sitnicka E, Ruscetti FW, Priestley GV et al. Transforming growth factor β1 directly and reversibly inhibits the initial cell division of long-term repopulating stem cells. Blood 1996;88:82-88.
11. Ottmann OG, Pelus LM. Differential proliferate effects of transforming growth factor-β on human hematopoietic progenitor cells. J Immunol 1988;140:2661-2665.
12. Sing GK, Keller JR, Ellingsworth LR et al. Transforming growth factor β selectively inhibits normal and leukemic human bone marrow cell growth in vitro. Blood 1988;72:1504-1511.
13. Cashman JD, Eaves AC, Raines EW et al. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. I. Stimulatory role of a variety of mesenchymal cell activators and inhibitory role of TGF-β. Blood 1990;75:96-101.
14. Hatzfeld J, Li ML, Brown EL et al. Release of early human hematopoietic progenitors from quiescence by antisense transforming growth factor β1 or Rb oligonucleotides. J Exp Med 1991;174:925-929.
15. Sargiacomo M, Valtieri M, Gabbianelli M et al. Pure human hematopoietic progenitors: direct inhibitory effect of transforming growth factors-β1 and -β2. Ann NY Acad Sci 1991;628:84-91.
16. - human umbilical cord blood cells reveals their potentiality to engraft adults. Proc Natl Acad Sci USA 1993;90:8707-8711.
17. + human hematopoietic progenitors. Exp Hematol 1996;24:1509-1515.
18. Fortunel N, Batard P, Hatzfeld A et al. High proliferative potential-quiescent cells: a working model to study primitive quiescent hematopoietic cells. J Cell Sci 1998;111:1867-1875.
19. Eaves CJ, Cashman JD, Kay RJ et al. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer. Blood 1991;78:110-117.
20. Nemunaitis J, Tompkins CK, Andrews DF et al. Transforming growth factor-β expression in human marrow stromal cells. Eur J Haematol 1991;46:140-145.
21. Moore SC, Theus SA, Barnett JB et al. Bone marrow natural suppressor cells inhibit the growth of myeloid progenitor cells and the synthesis of colony-stimulating factors. Exp Hematol 1992;20:1178-1183.
22. Lin HY, Wang XF, Ng-Eaton E et al. Expression of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell 1992;68:775-785.
23. Attisano L, Carcamo J, Ventura F et al. Identification of human activin and TGF-β type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993;75:671-680.
24. Franzen P, Ten Dijke P, Ichijo H et al. Cloning of a TGF-β type I receptor that forms a heteromeric complex with the TGF-β type II receptor. Cell 1993;75:681-692.
25. Ebner R, Chen RH, Shum L et al. Cloning of a type I TGF-β receptor and its effect on TGF-β binding to the type II receptor. Science 1993;260:1344-1348.
26. Wrana JL, Attisano L, Wieser R et al. Mechanism of activation of the TGF-β receptor. Nature 1994;370:341-347.
27. Massagué J. TGF-β signal transduction. Annu Rev Biochem 1998;67:753-791.
28. - progenitor cells. Blood 1991;77:1218-1227.
29. Brossard Y, Van Nifterik J, De Lachaux V et al. Collection of placental blood with a view to hemopoietic reconstitution. Nouv Rev Fr Hematol 1990;32:427-429.
30. Fauser AA, Messner HA. Granuloerylhropoietic colonies in human bone marrow, peripheral blood, and cord blood. Blood 1978;52:1243-1248.
31. Fauser AA, Messner HA. Identification of megakaryocytes, macrophages and eosinophils in colonies of human bone marrow containing neutrophilic granulocytes and erythroblasts. Blood 1979;53:1023-1027.
32. Cardoso AA. Characterisation of the human hematopoietic stem/progenitor cell compartment: implications for the biology and immunology of hematopoietic transplantation. Ph.D. Thesis, Université Paris XI, Faculté de Médecine Paris-Sud 1998.
33. Hatzfeld A, Batard P, Panterne B et al. Retroviral gene transfer in early hematopoietic progenitors released from quiescence. Hum Gene Ther 1996;7:207-213.
34. + hematopoietic progenitor cells. Leukemia 1994;8:441-445.
35. + hematopoietic progenitor cells from patients with myelofibrosis and myeloid metaplasia. Blood 1996;88:4534-4546.
36. Rooke HM, Vitas MR, Crosier PS et al. TGF-β type II receptor in chronic myeloid leukemia: analysis of microsatellite regions and gene expression. Leukemia 1999;13:535-541.
37. DeCoteau JF, Knaus PI, Yankelev H et al. Loss of functional cell surface transforming growth factor β (TGF-β) type I receptor correlates with insensitiviry to TGF-β in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1997;94:5877-5881.
38. Lagneaux L, Delforge A, Bron D et al. Heterogeneous response of B lymphocytes to transforming growth factor-β in B-cell chronic lymphocytic leukaemia: correlation with the expression of TGF-β receptors. Br J Haematol 1997;97:612-620.
39. Kadin ME, Cavaille-Coll MW, Gertz R et al. Loss of receptors for transforming growth factor-β in human T-cell malignancies. Proc Natl Acad Sci USA 1994;91:6002-6006.
40. Knaus PI, Lindemann D, DeCoteau JF et al. A dominant inhibitory mutant of the type II transforming growth factor-β receptor in the malignant progression of a cutaneous T-cell lymphoma. Mol Cell Biol 1996;16:3480-3489.
41. Markowitz S, Wang J, Myeroff L et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-1338.
42. Vincent F, Nagashima M, Takenoshita S et al. Mutation analysis of the transforming growth factor-β type II receptor in human cell lines resistant to growth inhibition by transforming growth factor-β. Oncogene 1997;15:117-122.
43. Park K, Kim SJ, Bang YJ et al. Genetic changes in the transforming growth factor β (TGF-β) type II receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-β. Proc Natl Acad Sci USA 1994;91:8772-8776.
44. Yang HK, Kang SH, Kim YS et al. Truncation of the TGF-β type II receptor gene results in insensitivity to TGF-β in human gastric cancer cells. Oncogene 1999;18:2213-2219.
45. Kim IY, Ahn HJ, Zelner DJ et al. Loss of expression of transforming growth factor β type I and type II receptors correlates with tumor grade in human prostate cancer tissues. Clin Cancer Res 1996;2:1255-1261.
46. Baldwin RL, Friess H, Yokoyama M et al. Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. Int J Cancer 1996;67:283-288.
47. Lazzereschi D, Ranieri A, Mincione G et al. Human malignant thyroid tumors displayed reduced levels of transforming growth factor β receptor type II messenger RNA and protein. Cancer Res 1997;57:2071-2076.
48. Reisenbichler H, Chari RS, Boyer IJ et al. Transforming growth factor-β receptors type I, II and III in phenobarbital-promoted rat liver tumors. Carcinogenesis 1994;15:2763-2767.
49. Bedossa P, Peltier E, Terris B et al. Transforming growth factor-β1 (TGF-β1) and TGF-β1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 1995;3:760-766.
50. Kimchi A, Wang XF, Weinberg RA et al. Absence of TGF-β receptors and growth inhibitory responses in retinoblastoma cells. Science 1988;240:196-199.
51. Horie K, Yamashita H, Mogi A et al. Lack of transforming growth factor-β type II receptor expression in human retinoblastoma cells. J Cell Physiol 1998;175:305-313.
52. Kim WS, Park C, Jung YS et al. Reduced transforming growth factor-β type II receptor (TGF-βRII) expression in adenocarcinoma of the lung. Anticancer Res 1999;19:301-306.
53. Wang XJ, Greenhalgh DA, Bickenbach JR et al. Expression of a dominant-negative type II transforming growth factor β (TGF-β) receptor in the epidermis of transgenic mice blocks TGF-mediated growth inhibition. Proc Natl Acad Sci USA 1997;94:2386-2391.
54. Amendt C, Schirmacher P, Weber H et al. Expression of a dominant negative type II TGF-β receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 1998;17:25-34.
55. Bottinger EP, Jakubczak JL, Haines DC et al. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbene-[a]-anthracene. Cancer Res 1997;57:5564-5570.
56. Bottinger EP, Jakubczak JL, Roberts IS et al. Expression of a dominant-negative mutant TGF-β type II receptor in transgenic mice reveals essential roles for TGF-β in regulation of growth and differentiation in the exocrine pancreas. EMBO J 1997;16:2621-2633.
57. Hata A, Shi Y, Massagué J. TGF-β signaling and cancer: structural and functional consequences of mutations in Smads. Mol Med Today 1998;4:257-262.
58. Hata A, Lo RS, Wotton D et al. Mutations increasing autoinhibition inactivate tumour suppressors Smad2 and Smad4. Nature 1997;388:82-87.
59. Takagi Y, Koumura H, Futamura M et al. Somatic alterations of the SMAD-2 gene in human colorectal cancers. Br J Cancer 1998;78:1152-1155.
60. Miyaki M, Iijima T, Konishi M et al. Higher frequency of Smad4 gene mutation in human colorectal cancer with distant metastasis. Oncogene 1999;18:3098-3103.
61. Kleeff J, Maruyama H, Friess H et al. Smad6 suppresses TGF-β-induced growth inhibition in COLO 357 pancreatic cancer cells and is overexpressed in pancreatic cancer. Biochem Biophys Res Commun 1999;255:268-273.
62. low cells in which anti-TGF-β upmodulates c-kit. Blood 1995;86:1729-1735.
63. Inagaki M, Moustakas A, Lin HY et al. Growth inhibition by transforming growth factor β (TGF-β) type I is restored in TGF-β-resistant hepatoma cells after expression of TGF-β receptor type II cDNA. Proc Natl Acad Sci USA 1993;90:5359-5363.
64. Chang J, Park K, Bang YJ et al. Expression of transforming growth factor β type II receptor reduces tumorigenicity in human gastric cancer cells. Cancer Res 1997;57:2856-2859.
65. Coppa A, Mincione G, Lazzereschi D et al. Restored expression of transforming growth factor β type II receptor in k-ras-transformed thyroid cells, TGF-β-resistant, reverts their malignant phenotype. J Cell Physiol 1997;172:200-208.
66. Wagner M, Kleef J, Lopez ME et al. Transfection of the type I TGF-β receptor restores TGF-β responsiveness in pancreatic cancer. Int J Cancer 1998;78:255-260.
67. Hunt KK, Fleming JB, Abramian A et al. Overexpression of the tumor suppressor gene Smad4/DCP4 induces p21waf1 expression and growth inhibition in human carcinoma cells. Cancer Res 1998;58:5656-5661.
68. Turco A, Coppa A, Aloe S et al. Overexpression of transforming growth factor β type II receptor reduces tumorigenicity and metastatic potential of K-ras-transformed thyroid cells. Int J Cancer 1999;80:85-91.